It is hoped that these transporters can replace the activity of the cystic fibrosis transmembrane conductance anion channel which is missing or dysfunctional in CF sufferers.
In collaboration with Professor David Sheppard of the School Physiology, Pharmacology and Neuroscience, the work will involve tests in human cells to validate the concept and prepare the way for clinical translation and commercialisation.